Navigation Links
Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer'
Date:2/7/2008

NEWPORT NEWS, Va., Feb 7 /PRNewswire/ -- Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, has appointed Robert G. Moussa to the position of President and Chief Executive Officer.

Moussa has a long and successful record in the medical device industry having held a number of senior positions at both Sherwood Medical Industries and Mallinckrodt Medical -- a health care corporation he ran as CEO for a number of years. In his four years at Mallinckrodt, Moussa grew revenues from $350 million to $1.2 billion and increased the operating margins from 18 percent to 22 percent. Additionally, he has successfully launched a number of new products in the diagnostic, nuclear medicine and medical device markets.

Dilon "the standard of care"

Regarding Dilon Moussa commented, "Dilon has advanced technology that will make it a major weapon in the battle against cancer. Based upon existing clinical results, it will become the standard of care as an adjunct diagnostic tool in the diagnosis of breast cancer."

4-Point Strategy

Under Moussa's leadership, Dilon will adopt a 4-point strategy to increase market share.
The strategy includes:

1) Expansion of the established installed base in the US through strategic

use of sales and distribution.

2) Initiating a major international expansion strategy. This is based on

Dilon's international potential of being at least as large as that in

the US.

3) Working with the Medical Establishment, expand the capabilities and

indications for the existing BSGI product.

4) Pursue acquisitions of products, technologies and companies that offer

a strategic fit with Dilon.

Moussa added, "I am confident that by adopting and accelerating these measures, we will achieve the objective of making Dilon the standard of care in the diagnostic field."

About Dilon Technologies LLC

<
'/>"/>
SOURCE Dilon Technologies LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
4. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. David Mott Appointed Non Executive Director at Shire
7. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
8. John Marshall and Kevin McGuinness Appointed to Ellex Board
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Capital ... solve complex business problems, is pleased to announce their ranking as one of the ... ranking of the fastest-growing private companies across the nation. , “It is truly an ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... Aug. 27, 2015 In response to ... UPS and The US Postal Service to no ... as ,select agents, by the CDC, Marken reaffirmed ... these sensitive shipments. Marken uses its ... trained and certified personnel to ensure the safe ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... Biodiesel Standards, VANCOUVER, British Columbia, June 20 ... night,s final vote by the ASTM,International D02 Main ... for biodiesel blends. After more than five years ... fuel experts in the,blended fuel balloting process, ASTM ...
... 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... Drug Administration (FDA) review, the Company is ... intravenous administration of REOLYSIN(R) in,combination with paclitaxel ... neck cancers. The Principal Investigator is Dr. ...
... GlaxoSmithKline (NYSE:,GSK) today announced that the U.S. ... in combination with tamsulosin for the,treatment of symptomatic ... men over 50 years old. The new indication ... medicines treats the symptoms of,enlarged prostate more effectively ...
Cached Biology Technology:Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 2Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 2FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 4
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... pioneering study of wild chimpanzees has found that these ... previous studies of captive individuals which had postulated that ... years of age. Together with recent data from ... week in the journal Current Biology -- suggests that ...
... from the University of Pennsylvania and Johns Hopkins University ... commonly activated proteins in cancer is so dangerous. ... protein can stop the production of at least 13 ... which genes are turned on and off. Furthermore, in ...
... people planning their day. Now with the help of NASA ... predictions of air quality, a feat that is becoming reality ... that an operational system of routine, global forecasts of air ... only a few years away. Such a system could prove ...
Cached Biology News:Wild chimpanzees appear not to regularly experience menopause 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2Air quality forecasts see future in space 2Air quality forecasts see future in space 3
... by BioLegend, the Quansys Biosciences Q-Plex Array ... of cytokines/chemokines for human, mouse, and rat ... a fully quantitative ELISA-based test where 4 ... each well of a 96-well plate in ...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: